Intraoperative NOL Titration

Sponsor
The Cleveland Clinic (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04679818
Collaborator
(none)
144
1
2
31
4.6

Study Details

Study Description

Brief Summary

To demonstrate that intraoperative NOL-guided titration of fentanyl improves initial recovery characteristics.

Condition or Disease Intervention/Treatment Phase
  • Drug: Routine opioid management
  • Device: PMD-200 Nol-guided opioid administration
Phase 3

Detailed Description

Previous work has shown that NOL accurately quantifies nociception during general anesthesia.6 Presumably, titrating opioids to NOL will therefore provide individual guidance so that patients will be given about the right amount. Patient given the right amount will presumably awaken quickly when anesthesia is done, and have good initial pain control in the PACU. To the extent that NOL titration facilitates optimal opioid dosing, patients are likely to have better PACU experiences - which would be an important outcome that clinicians and regulators are likely to take seriously.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
144 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Postoperative Consequences of Intraoperative NOL Titration
Actual Study Start Date :
Dec 30, 2020
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control Group

Clinicians will be blinded to PMD-200 NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when.

Device: PMD-200 Nol-guided opioid administration
PMD-200 NOL values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
Other Names:
  • PMD-200 NOL
  • Active Comparator: PMD-200 NOL group

    Clinicians will titrate fentanyl to keep PMD-200 NOL under 25 - always using good clinical judgement for individual patients

    Drug: Routine opioid management
    Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
    Other Names:
  • Fentanyl
  • Outcome Measures

    Primary Outcome Measures

    1. Pain Scores [60 minutes]

      The investigators will evaluate the pain scores at 10-minute using pain scores (0-10 verbal response scale)

    Secondary Outcome Measures

    1. Pain Scores <5. [60 minutes]

      The investigators will evaluate whether or not the pain score at any measured interval is < 5, using (0-10 verbal response scale)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adults having major non-cardiac surgery expected to last ≥2 hours

    • American Society of Anesthesiologists physical status 1-3

    • Age 21-85 years old

    • Planned endotracheal intubation

    Exclusion Criteria:
    • Planned neuraxial or regional block

    • Clinician preference for an opioid other than, or in addition to, fentanyl

    • Non-sinus heart

    • Neurologic condition that, in the opinion of the investigators, may preclude accurate assessment of postoperative pain and nausea

    • Lack of English language fluency

    • Routine user of psychoactive drugs other than opioids

    • Contraindication to sevoflurane, fentanyl, morphine, or ondansetron.

    • Intracranial surgery.

    • BMI > 40

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cleveland Clinic Cleveland Ohio United States 44195

    Sponsors and Collaborators

    • The Cleveland Clinic

    Investigators

    • Principal Investigator: Kurt Ruetzler, MD, The Cleveland Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Cleveland Clinic
    ClinicalTrials.gov Identifier:
    NCT04679818
    Other Study ID Numbers:
    • 19-1646
    First Posted:
    Dec 22, 2020
    Last Update Posted:
    Mar 8, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 8, 2022